The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study
Authors:
- 22 November 2025
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 135
Abstract
Neuroblastoma (NB) is a common pediatric malignant tumor, accounting for approximately 13% of childhood cancer-related deaths. It has a poor prognosis, and its pathogenesis and genetic characteristics remain complex. Although recent studies have suggested a potential association between immune cells and NB, the causal relationship remains unclear. In this study, we utilized genome-wide association studies (GWAS) summary statistics of 731 immune traits (n = 3757) and three NB subtypes: MYCN-amplified NB (n = 5369), 11q-deletion NB (n = 5222), and 1p-deletion NB (n = 5178). We conducted Mendelian randomization (MR) analyses to assess the causal relationship between immune cells (exposure) and these NB subtypes (outcome). After false discovery rate (FDR) correction, neither 11q-deletion NB nor 1p-deletion NB showed significant associations with immunophenotypes. However, and only one immunophenotype was positively correlated with the risk of MYCN-amplified NB: HLA DR on monocyte (OR: 1.754 [95% CI = 1.288 to 2.390], p = 3.6 × 10–4, q value = 0.194). Reverse MR analysis did not support a causal effect of MYCN-amplified NB on HLA DR expression in monocytes. Sensitivity analyses further confirmed the stability and reliability of these findings. Our MR study provides strong evidence for a causal relationship between HLA DR on monocyte and MYCN-amplified NB, suggesting that elevated HLA DR expression may be a risk factor for this aggressive subtype. These findings could inform clinical decision-making regarding prognosis and treatment strategies for MYCN-amplified NB and may also identify potential therapeutic targets.Keywords
This publication has 40 references indexed in Scilit:
- Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targetsJournal of Controlled Release, 2023
- Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral bloodTranslational Oncology, 2021
- The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncologyEuropean Journal of Cancer, 2021
- Molecular targeting therapies for neuroblastoma: Progress and challengesMedicinal Research Reviews, 2020
- Meta‐analysis andMendelianrandomization: A reviewResearch Synthesis Methods, 2019
- The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomicsHuman Mutation, 2018
- Clinical significance of MYCN amplification in patients with high‐risk neuroblastomaPediatric Blood & Cancer, 2018
- Impact of the physical microenvironment on tumor progression and metastasisCurrent Opinion in Biotechnology, 2016
- Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neonatal sepsisJournal of Infection, 2010
- The class II molecules of the human and murine major histocompatibility complexCell, 1984